# 2026-23141: FDA Says Dibenzyline Wasn't Pulled for Safety or Effectiveness

2026-23141, Determination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-11-13; PRIA reads it as touching household money (as of 2026-11-17).

- Canonical: https://policyrisk.com/federal-register/2026-23141
- As of: 2026-11-17
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-23141
- Title: Determination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 73252
- Published: 2026-11-13
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-17

## In one line

FDA Says Dibenzyline Wasn't Pulled for Safety or Effectiveness

## Summary

The FDA has decided that Dibenzyline (Phenoxybenzamine Hydrochloride) 10 mg capsules and some other drugs weren’t taken off the market because they’re unsafe or don’t work. This means generic versions can keep getting approved as long as they meet the rules. Patients and drug makers can breathe easy knowing these meds stay on the list and available.

## Abstract

The Food and Drug Administration (FDA or Agency) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.

## Effects PRIA read

- Generic Approvals Can Continue: benefit, medium. The FDA says it will continue to allow abbreviated new drug applications (ANDAs) that refer to the listed drugs to be approved if they meet legal and regulatory requirements. This specifically includes drugs listed in the notice such as DIBENZYLINE (Phenoxybenzamine Hydrochloride) 10 mg (NDA 008708…
- Existing Generic Approvals Unchanged: benefit, low. Approved ANDAs that refer to the listed drug products are unaffected by the products' discontinued marketing. For example, ANDAs that reference DIBENZYLINE (Phenoxybenzamine Hydrochloride) 10 mg (NDA 008708) remain approved.
- Products Listed as Discontinued (Not Safety Issues): benefit, low. The FDA will continue to list the named products in the Orange Book's "Discontinued Drug Product List," which identifies drugs discontinued from marketing for reasons other than safety or effectiveness. The notice names multiple products, including DIBENZYLINE (NDA 008708) and others on the table i…
- Possible Labeling Revisions for Applicants: cost, low. The FDA says that if it determines labeling for these drug products should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling. This applies to the drugs named in the notice, for example DIBENZYLINE (NDA 008708).

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-23141 on federalregister.gov](https://www.federalregister.gov/documents/2026/11/13/2026-23141/determination-that-dibenzyline-phenoxybenzamine-hydrochloride-oral-capsule-10-milligrams-and-other)
- [2026-23141 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-11-13/pdf/2026-23141.pdf)

## Related
- [Previous: 2026-23139, Environmental Impact Statements; Notice of Availability](https://policyrisk.com/federal-register/2026-23139)
- [Next: 2026-23142, South Atlantic Fishery Management Council; Public Meeting](https://policyrisk.com/federal-register/2026-23142)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-23141 (as of 2026-11-17).
